Tag: BREAST CANCER

American Medical AssociationLooking for the Optimal Endocrine Partner for ER+, HR+, ERBB2- Advanced Breast Cancer

A phase 2 clinical trial involving 486 patients examined whether fulvestrant or letrozole is more effective in treating advanced breast cancer. The results, published in JAMA Oncology, confirmed that letrozole is the preferred treatment in patients with advanced forms of breast cancer. Although fulvestrant demonstrated significant antitumor activity, it did not significantly impact the overall […]

American Medical AssociationAssessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer

Publication: JAMA Oncology Design: An analysis of data from the I-SPY2 randomized clinical trial that included 938 women with breast cancer.Results: In this randomized clinical trial, the prognostic significance of RCB was consistent regardless of cancer subtype and treatment.

American Society of Clinical OncologyBreast Cancer Prevention: Time for Change

In this comprehensive Journal of Clinical Oncology clinical review, the authors suggest that reexamination of breast cancer risk reduction strategies and clinical practice is needed. Prediction models, breast cancer mortality, prognostic categories, and the Women’s Health Initiative (WHI) randomized trials, dietary modification (DM) trial, hormone therapy trials, estrogen, and estrogen plus progestin trials are all […]

American Society of HematologyA Bleeding Diathesis in a 65-Year-Old Woman with Newly Diagnosed Breast Cancer

After diagnosis during a partial mastectomy, this patient’s estimated blood loss was 58 mL, causing anemia and requiring a red blood cell transfusion along with ventriculoperitoneal drain placement. With a substantive bleeding history before the diagnosis, what would you do next with this patient? Work her up for von Willebrand disease? Do a complete blood […]

Wyanoke GroupFDA Grants Fast Track Status to Cosela for Triple-Negative Breast Cancer (TNBC)

Trilaciclib (Cosela, G1 Therapeutics), a cyclin dependent kinase 4/6 inhibitor, is already approved in the United States to reduce frequency of chemotherapy-related bone marrow suppression among adults with extensive-stage small cell lung cancer. Now, the FDA has granted fast track designation to the drug for use in combo with chemo for treatment of locally advanced […]

American Medical AssociationEffect of Celecoxib vs. Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients with Breast Cancer

Is there a benefit for patients who receive celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)–negative primary breast cancer? A report on the Randomized European Celecoxib Trial (REACT), a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing two years of adjuvant celecoxib vs. […]

American Medical AssociationAssessment of 25-Year Survival of Women with ER+/ERBB2- Breast Cancer Treated w. and without Tamoxifen Therapy

This Original Investigation from JAMA Network Open assesses whether clinically used markers of breast cancer, such as tumor size, tumor grade, progesterone receptor status, and Ki-67 status, are associated with long-term (25-year) survival as they are with short-term survival. The study was a secondary analysis of data from a subset of 565 women who participated […]

American Medical AssociationAssociation of Breast Cancer Irradiation With Cardiac Toxic Effects

In this JAMA Oncology Narrative Review, the authors attempt to discover whether cardiovascular risks may be associated with the multimodal approach, including systemic therapies and breast radiotherapy (RT), in treating breast cancer patients. Although recent advancements in breast cancer treatment have led to a decrease in mortality rates, the prevalence of survivors with a potentially […]

American Medical AssociationSurvival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status

In this JAMA Surgery Original Investigation, the researchers fielded a Swedish cohort study of 48,986 women to discover whether breast conservation offers a survival benefit compared with mastectomy when results are adjusted for main confounders such as comorbidity and socioeconomic status. The main outcomes and measures were overall survival (OS) and breast cancer–specific survival (BCSS).